NewAmsterdam Pharma (NAMS) EBITDA (2023 - 2026)
NewAmsterdam Pharma (NAMS) EBITDA from Mar 31, 2023 to Mar 31, 2026. The TTM NewAmsterdam Pharma (NAMS) EBITDA is -$215M. You can adjust inflation or export chart.
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Annual EBITDA
Quarterly EBITDA
NewAmsterdam Pharma (NAMS) EBITDA CAGR table
| Period | CAGR |
|---|---|
| 1 Year TTM | +13.38% |
| 3 Years TTM | +75.39% |
| All Time TTM | +4.05% |
Annual EBITDA change of NewAmsterdam Pharma (NAMS)
| Year | EBITDA | Change |
|---|---|---|
| 2026 | -$58M | -74.12% |
| 2025 | -$225M | +27.97% |
| 2024 | -$176M | -3.68% |
| 2023 | -$183M | +171.03% |
| 2022 | -$67M | +126.32% |
| 2021 | -$30M | +449.17% |
| 2020 | -$5.43M | N/A |